257.19
Alnylam Pharmaceuticals Inc stock is traded at $257.19, with a volume of 941.28K.
It is up +0.92% in the last 24 hours and down -4.20% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$254.85
Open:
$256.14
24h Volume:
941.28K
Relative Volume:
1.08
Market Cap:
$30.64B
Revenue:
$2.25B
Net Income/Loss:
$-278.16M
P/E Ratio:
-118.52
EPS:
-2.17
Net Cash Flow:
$-42.59M
1W Performance:
+8.63%
1M Performance:
-4.20%
6M Performance:
-9.66%
1Y Performance:
+74.53%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-31-25 | Initiated | Redburn Atlantic | Buy |
Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-29-23 | Initiated | Raymond James | Outperform |
May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Apr-26-23 | Initiated | SMBC Nikko | Neutral |
Mar-21-23 | Initiated | Bernstein | Outperform |
Jan-18-23 | Initiated | Canaccord Genuity | Buy |
Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
Jun-07-22 | Initiated | William Blair | Outperform |
Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mar-01-22 | Initiated | Citigroup | Buy |
Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-04-21 | Upgrade | UBS | Neutral → Buy |
Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Sep-30-20 | Resumed | Berenberg | Hold |
Sep-08-20 | Initiated | Citigroup | Buy |
Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
Apr-24-20 | Resumed | Evercore ISI | Outperform |
Mar-19-20 | Initiated | Berenberg | Buy |
Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
Nov-20-19 | Initiated | Oppenheimer | Outperform |
Nov-13-19 | Initiated | BofA/Merrill | Buy |
May-23-19 | Resumed | Goldman | Neutral |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-23-19 | Initiated | UBS | Neutral |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Aug-13-18 | Reiterated | Stifel | Buy |
Aug-07-18 | Upgrade | Stifel | Hold → Buy |
May-04-18 | Reiterated | Stifel | Hold |
Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Alnylam (ALNY) and Halozyme (HALO) Secure EMA Panel Endorsements - GuruFocus
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - BioSpace
Gene Therapy Market Statistics 2025-2033 | Regional Breakdown & - openPR.com
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In Europe - simplywall.st
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Alnylam, Halozyme among latest firms to win EU backing for drugs (HALO:NASDAQ) - Seeking Alpha
European Regulators Endorse Breakthrough ATTR-CM Treatment as Alnylam Hits All 10 Trial Endpoints - Stock Titan
Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency - marketscreener.com
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Tr - GuruFocus
Alnylam (ALNY) Secures EMA Committee Support for Expanded Use of Vutrisiran | ALNY Stock News - GuruFocus
Alnylam’s vutrisiran gets positive CHMP opinion for ATTR-CM - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Alnylam (ALNY) Gains Positive CHMP Opinion for Amvuttra Label Ex - GuruFocus
Alnylam stock rises following CHMP’s positive opinion on Amvuttra By Investing.com - Investing.com Nigeria
Homozygous Familial Hypercholesterolemia Market Poised - openPR.com
Cns Specific Antisense Oligonucleotide Market Generated - openPR.com
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline - Yahoo Finance
ATTR Amyloidosis Pipeline: 10+ Leading Companies Shaping the Future of Groundbreaking Therapies | DelveInsight - openPR.com
Transthyretin Amyloidosis Treatment Market: Revenue Growth - openPR.com
How Do Investors Really Feel About Alnylam Pharmaceuticals? - Benzinga
BofA Raises Price Target on Alnylam (ALNY) Ahead of Q1 Earnings - GuruFocus
Rnai Technology Market to Witness Massive Growth by 2032 | - openPR.com
Huntingtons Disease Treatment Market Projected To Witness - openPR.com
BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating - marketscreener.com
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results | ALNY Stock News - GuruFocus
Earnings Preview: RNAi Leader Alnylam Set to Unveil Q1 2025 Performance May 1What to Watch - Stock Titan
Coagulation Factor Deficiency Therapeutics Market Size in 7MM - openPR.com
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
RNAi Therapeutics and Technology Market Key Players Analysis - openPR.com
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires? - Insider Monkey
10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey
High Growth Tech Stocks In US With Potential For Expansion - Yahoo Finance
Morgan Stanley Lowers Alnylam (ALNY) Price Target Amid Earnings Preview | ALNY Stock News - GuruFocus
Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? - MSN
Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive - Endpoints News
Alnylam at 24th Annual Needham Conference: Strategic Growth in Focus By Investing.com - Investing.com Australia
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? - Insider Monkey
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):